Quince Therapeutics (Nasdaq:QNCX) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

QNCX 주식 개요

바이오 제약 회사인 Quince Therapeutics는 쇠약성 및 희귀 질환 환자를 위한 치료제를 확보, 개발 및 상용화하는 데 주력하고 있습니다.

QNCX 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

지난 5년간 매년 수익이 1.7% 씩 감소했습니다.

의미 있는 시가총액이 없습니다. ( $29M )

지난 1년 동안 주주가 희석되었습니다.

Quince Therapeutics, Inc. 경쟁사

Gain Therapeutics

NasdaqGM:GANX

US$32.2m

Neoleukin Therapeutics

NasdaqCM:NLTX

US$32.8m

Vaxxinity

OTCPK:VAXX

US$31.6m

Exagen

NasdaqGM:XGN

US$31.6m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Quince Therapeutics
과거 주가
현재 주가	US$0.72
52주 최고치	US$1.70
52주 최저치	US$0.63
베타	1.16
11개월 변경	-12.65%
3개월 변경 사항	-30.95%
1년 변경 사항	-50.68%
33년 변화	-98.69%
5년 변화	-98.08%
IPO 이후 변화	-97.80%

최근 뉴스 및 업데이트

Recent updates

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Nov 21

Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares

Mar 10

Companies Like Cortexyme (NASDAQ:CRTX) Are In A Position To Invest In Growth

Feb 09

Cortexyme: A Fresh Perspective In Alzheimer's

Jan 12

주주 수익률

	QNCX	US Biotechs	US 마켓
7D	2.8%	-1.9%	0.5%
1Y	-50.7%	10.4%	20.5%

수익률 대 산업: QNCX 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: QNCX 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is QNCX's price volatile compared to industry and market?
QNCX volatility
QNCX Average Weekly Movement	8.0%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	2.8%

안정적인 주가: QNCX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: QNCX 의 주간 변동성( 8% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2012	32	Dirk Thye	www.quincetx.com

바이오 제약 회사인 Quince Therapeutics는 쇠약성 및 희귀 질환 환자를 위한 치료제를 확보, 개발 및 상용화하는 데 주력하고 있습니다. 이 회사의 주요 자산 후보군은 ATM 유전자 돌연변이로 인한 유전성 상염색체 열성 신경 퇴행성 및 면역 결핍 질환인 A-T를 포함한 희귀 소아 신경 퇴행성 질환 치료를 위한 에리덱스로 구성되어 있습니다. 자동화된 공정을 통해 환자 자신의 적혈구에 약물을 캡슐화하는 약물/기기 결합 플랫폼인 AIDE 기술 플랫폼은 자동화 장비인 RCL, 멸균 일회용 소모성 치료 키트인 EryKit, 시린지 키트, 약물 및 공정 솔루션으로 구성되어 있습니다.

Quince Therapeutics, Inc. 기본 사항 요약

Quince Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
QNCX 기본 통계
시가총액	US$32.41m
수익(TTM)	-US$30.28m
수익(TTM)	n/a

0.0x

P/S 비율

-1.0x

P/E 비율

QNCX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
QNCX 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$30.28m
수익	-US$30.28m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.70
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	18.2%

QNCX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

QNCX 주식 개요

보상

위험 분석

Quince Therapeutics, Inc. 경쟁사

NasdaqGM:GANX

US$32.2m

NasdaqCM:NLTX

US$32.8m

OTCPK:VAXX

US$31.6m

NasdaqGM:XGN

US$31.6m

가격 내역 및 성능

최근 뉴스 및 업데이트

Quince Therapeutics Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Quince Therapeutics, Inc. Launches Scientific Advisory Board

Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors

CEO & Director exercised options to buy US$336k worth of stock.

Recent updates

Quince Therapeutics Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Quince Therapeutics, Inc. Launches Scientific Advisory Board

Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors

CEO & Director exercised options to buy US$336k worth of stock.

Independent Chairman of the board recently bought US$58k worth of stock

Quince Therapeutics Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer

Insufficient new directors

New minor risk - Shareholder dilution

Quince Therapeutics, Inc. Appoints Luca Benatti as Director

Quince Therapeutics, Inc. (NasdaqGS:QNCX) acquired EryDel S.p.A. for approximately $510 million.

Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug (Ind) Application for Its Lead Phase 3 Asset, Erydex

Quince Therapeutics Appoints Charles S. Ryan as President

Independent Chairman of the board recently bought US$108k worth of stock

Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023

CEO, President & Director recently bought US$99k worth of stock

New minor risk - Share price stability

Quince Therapeutics, Inc. (NasdaqGS:QNCX) agreed to acquire EryDel S.p.A. for approximately $490 million.

Biomed Industries, Inc. submitted a proposal to acquire Quince Therapeutics, Inc. (NasdaqGS:QNCX) for $10.5 million.

Price target increased by 56% to US$12.00

Quince Therapeutics Gets an Initial Compliance Period of 180 Calendar Days to Regain Compliance with the Minimum Bid Price Requirement

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Insufficient new directors

Insufficient new directors

Quince Therapeutics, Inc. Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures

Price target increased to US$8.38

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

Cortexyme to change name and ticker symbol next month

Cortexyme, Inc. Announces Resignation of Leslie Holsinger as Executive Vice President of Research and Development, Effective July 31, 2022

Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 2000 Dynamic Index

Cortexyme, Inc. Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

Cortexyme, Inc. Appoints June Bray to its Board of Directors

Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer

Cortexyme, Inc. (NasdaqGS:CRTX) acquired Novosteo Inc. from David Lamond and others for $19.8 million.

Dr. Dirk Thye and Philip Low to Join Cortexyme Board

Price target decreased to US$7.60

Cortexyme, Inc. Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of Its Phase 1 Clinical Trial of Cor588

Price target decreased to US$7.60

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

Cortexyme, Inc. Announces Executives Changes

Cortexyme, Inc. Receives Letter from the U.S. Food and Drug Administration, Placing Full Clinical Hold on Atuzaginstat’s (COR388) Investigational New Drug Application

Price target increased to US$44.00

Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors

We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

COO, CFO & Treasurer exercised options to buy US$387k worth of stock.

Cortexyme: A Challenging Path Forward

Cortexyme: Positive Lessons To Be Learned From Disappointing Results

Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease

COO, CFO & Treasurer exercised options and sold US$217k worth of stock

Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021

Cortexyme: Alzheimer's Readout In November A Binary Event

Cortexyme, Inc. Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

Price target increased to US$97.71

Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit

We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth

Price target increased to US$89.00

Price target increased to US$78.29